271 related articles for article (PubMed ID: 21350850)
21. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
22. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects.
Greene SA; Kwak C; Kamin M; Vernillet L; Glenn KJ; Gabriel L; Kim HW
Clin Transl Sci; 2022 Apr; 15(4):899-911. PubMed ID: 34877801
[TBL] [Abstract][Full Text] [Related]
23. Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
Dai X; Karol MD; Hitron M; Hard ML; Goulet MT; McLaughlin CF; Brantley SJ
Clin Pharmacol Drug Dev; 2021 Aug; 10(8):824-839. PubMed ID: 34107166
[TBL] [Abstract][Full Text] [Related]
24. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
Wang J; Zhang ZY; Lu S; Powers D; Kansra V; Wang X
Support Care Cancer; 2019 Mar; 27(3):819-827. PubMed ID: 30084103
[TBL] [Abstract][Full Text] [Related]
25. Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers.
Doroshyenko O; Rokitta D; Zadoyan G; Klement S; Schläfke S; Dienel A; Gramatté T; Lück H; Fuhr U
Drug Metab Dispos; 2013 May; 41(5):987-93. PubMed ID: 23401474
[TBL] [Abstract][Full Text] [Related]
26. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
[TBL] [Abstract][Full Text] [Related]
27. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
Minami H; Kawada K; Ebi H; Kitagawa K; Kim YI; Araki K; Mukai H; Tahara M; Nakajima H; Nakajima K
Cancer Sci; 2008 Jul; 99(7):1492-8. PubMed ID: 18477034
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study.
Desch M; Schlecker C; Hohl K; Liesenfeld KH; Chan T; Müller F; Wunderlich G; Keller S; Ishiguro N; Wind S
J Clin Psychopharmacol; 2023 Mar-Apr 01; 43(2):113-121. PubMed ID: 36700734
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory effects of kale ingestion on metabolism by cytochrome P450 enzymes in rats.
Yamasaki I; Yamada M; Uotsu N; Teramoto S; Takayanagi R; Yamada Y
Biomed Res; 2012; 33(4):235-42. PubMed ID: 22975634
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.
Rowland A; van Dyk M; Warncken D; Mangoni AA; Sorich MJ; Rowland A
Br J Clin Pharmacol; 2018 Mar; 84(3):501-509. PubMed ID: 29178272
[TBL] [Abstract][Full Text] [Related]
33. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Backman JT; Mäenpää J; Belle DJ; Wrighton SA; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Apr; 67(4):382-90. PubMed ID: 10801247
[TBL] [Abstract][Full Text] [Related]
34. Effect of colchicine on rat hepatic cytochrome P450 enzymes by cocktail probe drugs.
Xu BB; Xu ZS; Zheng SL; Tang CR
Pharmazie; 2014 Jan; 69(1):43-7. PubMed ID: 24601222
[TBL] [Abstract][Full Text] [Related]
35. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
Kakuda TN; Van Solingen-Ristea RM; Onkelinx J; Stevens T; Aharchi F; De Smedt G; Peeters M; Leopold L; Hoetelmans RM
J Clin Pharmacol; 2014 Apr; 54(4):422-31. PubMed ID: 24165884
[TBL] [Abstract][Full Text] [Related]
36. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
37. A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng.
Seong SJ; Kang WY; Heo JK; Jo J; Choi WG; Liu KH; Lee S; Choi MK; Han YH; Lee HS; Ohk B; Lee HW; Song IS; Yoon YR
Clin Ther; 2018 Aug; 40(8):1322-1337. PubMed ID: 30078466
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.
Tran JQ; Othman AA; Wolstencroft P; Elkins J
Br J Clin Pharmacol; 2016 Jul; 82(1):160-7. PubMed ID: 26991517
[TBL] [Abstract][Full Text] [Related]
39. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
40. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Ogasawara K; LoRusso PM; Olszanski AJ; Rixe O; Xu C; Yin J; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 Jul; 86(1):87-95. PubMed ID: 32537715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]